相关实验视频
Updated: Sep 13, 2026

08:38
Habituation and Prepulse Inhibition of Acoustic Startle in Rodents
Published on: September 1, 2011
75.5K
布雷克西普拉用于阿尔茨海默病的激发:随机对照试验的系统审查和元分析
João Vitor Andrade Fernandes1, João Victor de Oliveira Ramos1, Laís Araújo Dos Santos Vilar1
1Medical Sciences Center, Federal University of Paraíba, Brazil.
Indian journal of psychiatry
|September 29, 2025
概括
与安慰剂相比,布雷克西普拉2毫克有效地减少了阿尔茨海默氏病 (AD) 患者的激动. 虽然副作用增加,但严重事件和死亡率没有显著差异,这表明这种剂量具有有利的安全性.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 老年病的医生 老年病的医生
背景情况:
- 兴奋是阿尔茨海默病患者及其护理人员面临的重大挑战.
- 布雷克西普拉是一种血清素-多巴胺调节剂,目前正在研究与AD相关的激动性.
- 布雷克斯皮普拉的最佳剂量和安全性需要进一步评估.
研究的目的:
- 评估布雷克斯皮普拉在阿尔茨海默氏病中治疗兴奋的疗效和安全性.
- 分析布雷克斯皮普拉治疗的剂量特定结果.
主要方法:
- 在PubMed,Embase和Cochrane图书馆中对随机对照试验 (RCT) 的系统文献搜索.
- 四个涉及1710名参与者的RCT的元分析,比较布雷克斯皮普拉佐与安慰剂.
- 评估初级疗效结果 (CMAI,CGI-S得分) 和安全结果 (TEAE,SAE,死亡率).
主要成果:
- 布雷克西普拉2毫克显著降低了兴奋 (CMAI得分) 和严重性 (CGI-S得分) 与安慰剂相比 (P <0.001和P = 0.008).
- 较低的布雷克西普拉剂量 (0.5-1毫克) 显示出有限的疗效.
- 治疗出现的不良事件 (TEAE) 在布雷克斯皮普拉2毫克 (P = 0.030) 中更频繁,但严重的不良事件和死亡率与安慰剂相比.
结论:
- 服用2毫克的布雷克斯皮普拉在缓解阿尔茨海默氏病动荡症状方面表现出显著的疗效.
- 布雷克西普拉的2毫克剂量呈现出可接受的安全性概况,用于管理AD相关的激动.
相关概念视频
Psychosis and Antipsychotic Drugs: Overview
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications

